Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Dividend Discount Model (DDM)
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Regeneron Pharmaceuticals Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
The financial data reveals notable trends in share price, earnings per share (EPS), and price-to-earnings (P/E) ratio over the analyzed periods.
- Share Price
- The share price started relatively low in the early years, approximately $16.37 in 2006, with modest fluctuations until 2010. From 2010 onward, a significant upward trend is evident, with the share price climbing sharply to reach a peak of $936.33 in 2024. Notably, there were strong gains between 2010 and 2015, followed by a brief plateauing and some volatility. The price experienced a decline in 2025 to $716.72, indicating some correction after reaching its peak.
- Earnings Per Share (EPS)
- EPS exhibited a generally negative trajectory until 2011, indicative of losses with a gradual reduction in negative values from -1.68 to -1.16. Starting in 2012, EPS shows a marked turnaround to positive territory, peaking at 74.4 in 2022. There was a very sharp increase in EPS between 2013 and 2022, suggesting strong profitability growth. After reaching a high in 2022, EPS declined to 36.02 in 2024 but rose again to 40.36 in 2025, indicating some volatility yet sustained positive earnings.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio data is available from 2014 onward and shows significant fluctuations. Initially, the P/E ratio was elevated at 21.42 in 2014, soaring to 118.44 in 2016, reflecting market expectations of future earnings growth or elevated valuation during that period. This high valuation corrected over subsequent years, decreasing steadily to 8.37 in 2020, which may indicate a period of either increased earnings or market reevaluation reducing the price relative to earnings. Thereafter, the P/E ratio rose again to 19.68 in 2021 and 25.99 in 2022 before declining to 17.76 in 2024, showing moderate valuation adjustments in line with earnings and share price movements.
In summary, the share price and EPS data show a turnaround from losses to strong earnings growth, driving substantial increases in share value. The P/E ratio’s volatility suggests changing market sentiment regarding the company's valuation, with periods of both high optimism and more conservative pricing relative to earnings.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | ||||||||||||
| Feb 5, 2024 | ||||||||||||
| Feb 6, 2023 | ||||||||||||
| Feb 7, 2022 | ||||||||||||
| Feb 8, 2021 | ||||||||||||
| Feb 7, 2020 | ||||||||||||
| Feb 7, 2019 | ||||||||||||
| Feb 8, 2018 | ||||||||||||
| Feb 9, 2017 | ||||||||||||
| Feb 11, 2016 | ||||||||||||
| Feb 12, 2015 | ||||||||||||
| Feb 13, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 21, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 18, 2010 | ||||||||||||
| Feb 26, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Mar 12, 2007 | ||||||||||||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).